• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Chiesi acquires rights to Third Pole’s tankless iNO delivery system

Third Pole Therapeutics has announced a deal with Chiesi Farmaceutici giving Chiesi global rights to develop and commercialize Third Pole’s tankless inhaled nitric oxide (iNO) delivery system for the treatment of infants with hypoxic respiratory failure in neonatal intensive care. Third Pole had previously announced a strategic collaboration agreement with Johnson & Johnson subsidiary Actelion in March 2019.

In May 2017, Third Pole’s iNO technology won the Johnson & Johnson Innovation – JLABS @ M2D2 QuickFire Challenge. The company’s tankless, on-demand iNO delivery technology is protected by numerous patents.

Third Pole CEO Bill Athenson commented, “Chiesi’s essential, high quality products, and its sales and marketing team’s respected presence in nearly every neonatal intensive care unit will facilitate rapid early adoption of Third Pole’s device, a tankless platform that generates iNO in unlimited quantities by combining room air with electricity. The combination of tankless portable technology and Chiesi Group’s global reach could dramatically expand access to life-sustaining iNO and fulfill a very large and long-standing unmet worldwide need.”

Chiesi Group Global Strategy & Corporate Development Head Giovanna Amadori said, “This partnership is a concrete demonstration of Chiesi’s continuous commitment to embrace state-of-the-art technologies, with the aim of providing patients and their caregivers with innovative solutions to improve their quality of life. When approved, Third Pole will offer a truly tankless and reagent free solution for iNO delivery.”

Read the Third Pole Therapeutics press release.

Share

published on April 8, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews